Tandem Set for M&A in One of Diabetes Tech Most Eventful Years

2022 might almost be over, but that isn’t stopping Tandem Diabetes Care from getting involved in M&A. It also adds one more development in a busy year for diabetes tech.

The San Diego, CA-based company said it was acquiring AMF, the developer of the Sigi Patch Pump.

“This acquisition supports our commitment to drive growth through innovation, as AMF Medical has novel technology and a shared passion for creating easy-to-use solutions to improve the lives of people with diabetes,” said John Sheridan, Tandem Diabetes Care president and chief executive officer. “Our portfolio approach to diabetes care is designed to bring the benefits of advanced insulin pump therapy to more people worldwide, utilize our expertise in automated insulin delivery technology and data management, and leverage our commercial infrastructure to create shareholder value.”

The deal is set to close in January and includes the following details:

Tandem kicked off 2022 by winning FDA clearance of bolus insulin dosing on the t:slim X2 insulin pump using the t:connect mobile app. The company touted the nod represented the first-ever FDA-cleared smartphone application capable of initiating insulin delivery on both iOS and Android operating systems.